Range Biotechnologies, a prominent biotech company based in San Francisco, California, has successfully secured $5.2 million in Seed funding to support its groundbreaking work in proteomics. The funding round was led by Artis Ventures, a renowned venture capital firm, with participation from notable investors such as Pear VC, Page One Ventures, Civilization Ventures, Pillar, Four Cities Capital, Hawktail, and others. As a result of this investment, Ameena El-Bibany, a Partner at ARTIS Ventures, has joined Range Biotechnologies’ Board of Directors.
The company plans to utilize the raised funds to propel its research and development efforts in high throughput multiplexed protein quantification, aiming to revolutionize precision health. Founded by Dr. Brandon Wilson, Dr. Nicolo Maganzini, and Professor Tom Soh from Stanford University, Range Biotechnologies is at the forefront of developing innovative tools that unlock the potential of translational proteomics and enable personalized healthcare solutions.
Range Biotechnologies’ pioneering technology allows for the precise and simultaneous quantification of multiple proteins across numerous samples, providing invaluable insights into the underlying mechanisms of diseases and their dynamic changes over time. By building a robust tech platform, the company aims to unlock new possibilities in various markets, including pharmacodynamics, diagnostic medicine, drug discovery, food safety, and liquid biopsy.
The vision of Range Biotechnologies is to enable a new era of personalized healthcare by leveraging their cutting-edge proteomics technology. With a focus on advancing precision health, the company is dedicated to transforming how diseases are understood, diagnosed, and treated. Through their innovative approach, Range Biotechnologies aims to create a positive impact on patient care and contribute to the advancement of medical science.